



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

## Revision of Precautions

### Sitagliptin phosphate hydrate

March 24, 2015

#### **Non-proprietary name**

Sitagliptin phosphate hydrate

#### **Safety measure**

Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following texts should be added (underlined parts are revised):

#### Thrombocytopenia:

Thrombocytopenia may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.